On the morning of January 10, the atmosphere at the Radisson Hotel in Xinxiang International Conference Center was both lively and solemn. Representatives from universities and enterprises, along with distinguished guests, gathered for the "Release of Xinxiang City's 'Ten Measures' to Deepen University-Enterprise-Local Cooperation and the Centralized Signing Ceremony for Collaborative Projects." Li Wei, General Manager of EMICRO Biomedicine Company, and Jin Jianxin, Deputy General Manager, took the stage to sign agreements on behalf of Henan Normal University and EMICRO Biomedicine Company, respectively.  

To fully leverage the resource advantages of university-enterprise-local collaboration and promote technological innovation and high-quality economic development, Xinxiang City issued the "Several Measures by the CPC Xinxiang Municipal Committee and Xinxiang Municipal People's Government on Further Deepening University-Enterprise-Local Cooperation" and organized a large-scale signing event. On the day of the conference, a total of 80 university-enterprise-local cooperation projects were signed. EMICRO Biomedicine, as one of the 50 representatives, took the stage in the first group to sign. Li Wei, General Manager of EMICRO Biomedicine and a professor at the School of Chemical Engineering of Henan Normal University, was invited to speak as a representative of the university.  

General Manager Li Wei stated that Henan EMICRO Biomedicine Company is a product of university-enterprise cooperation, and he himself is both a practitioner and witness of such collaboration. Since its establishment, with the strong support of the Xinxiang Municipal Party Committee and Government, EMICRO Biomedicine has achieved fruitful results through university-enterprise cooperation. The company has invested a total of 150 million yuan, focusing on the research and development of new anti-cancer drugs, filling multiple gaps in Xinxiang City and even Henan Province. Among these, the anti-cancer drug TM471, independently developed through university-enterprise cooperation, has entered Phase I clinical trials. Currently, multiple patients have been successfully enrolled, and preliminary results show that the drug is highly effective with low toxicity. In one case, the tumor lesion shrank by 51% after two months of treatment, surprising the clinical experts.  

It is university-enterprise cooperation that has given rise to high-tech innovation enterprises, incubated advanced research platforms, and yielded substantial results. Such collaboration has facilitated the exchange of talent and research resources, enabling enterprises to compete in the international field of innovative drugs.  

In his speech, General Manager Li expressed gratitude for the municipal government's "Ten Measures." He mentioned that innovative drug development requires significant funding and has a long cycle, and the current cooling of the capital market could adversely affect enterprise development. He hopes that the municipal government will coordinate resources to strongly support drug innovation research, striving to achieve "dual listings" for both drugs and enterprises, accelerate the transformation of scientific research results, benefit society, and drive the healthy development of the biomedical industry in the city and the province.  

The day's conference and signing ceremony were presided over by Wei Jianping, Mayor of Xinxiang City, with Li Weidong, Secretary of the Xinxiang Municipal Party Committee, delivering a speech. Leaders from provincial departments such as the Organization Department, the Department of Industry and Information Technology, and the Department of Science and Technology, as well as relevant leaders from the municipal party committee and government, attended the event.